 |
Visudyne
|
| Overview |
 Visudyne® (verteporfin) was the first therapeutic treatment approved worldwide for certain forms of wet age-related macular degeneration (AMD), the leading cause of blindness in people over the age of 55.
It is commercially available in 77 countries for the treatment of classic subfoveal choroidal neovascularization (CNV), and in a number of countries for occult subfoveal CNV, both caused by AMD.
Over the past three years the use of combination treatments has evolved. Currently there are a number of clinical trials investigating the combination of newer agents, such as anti-VEGF with Visudyne to evaluate potential benefits including: improved visual gains, durable effects of therapy, convenience for patients and practitioners, and cost effectiveness.
QLT has a co-development agreement with Novartis AG. Under the terms of the agreement QLT is responsible for manufacturing Visudyne, and Novartis AG markets and distributes the product.
Please visit the Visudyne Web site, for additional product information, patient and practitioner information, clinical centers, AMD resources and Visudyne availability.
You can also call to get more information about Visudyne, such as locating a physician who treats age-related macular degeneration (AMD) with Visudyne and reimbursement of treatment costs by calling 1.877.736.2778. |
|
| Visudyne® is a registered trademark of Novartis AG |
|
|
|
|
|
|
|
|
